Is more the better?—cetuximab in non-small cell lung cancer patients

Por Moran, Teresa
Publicado no Transl Lung Cancer Res (2018)

A new era of treating advanced lung cancer is upon us

Por Weiss, Glen J.
Publicado no Transl Lung Cancer Res (2018)

No room for statins in the quest for survival benefits in small cell lung cancer

Por Facchinetti, Francesco, Tiseo, Marcello
Publicado no Transl Lung Cancer Res (2018)

Tobacco cessation in lung cancer screening—do we have the evidence?

Por Stone, Emily, Marshall, Henry
Publicado no Transl Lung Cancer Res (2018)

Highlights in the 14(th) Central European Lung Cancer Conference (CELCC)

Por Li, Grace
Publicado no Transl Lung Cancer Res (2014)

Reflections on immune checkpoint inhibition in non-small cell lung cancer

Por Leventakos, Konstantinos, Mansfield, Aaron S.
Publicado no Transl Lung Cancer Res (2014)

Necitumumab: a new therapeutic option for squamous cell lung cancer?

Por Pillai, Rathi N., Ramalingam, Suresh S.
Publicado no Transl Lung Cancer Res (2014)

Highlights in management of early stage non-small cell lung cancer

Por Li, Grace
Publicado no Transl Lung Cancer Res (2013)

Exploring controversies in lung cancer using structured pro-con debates

Por Senan, Suresh
Publicado no Transl Lung Cancer Res (2015)

Tumor cell proliferation, proliferative index and mitotic count in lung cancer

Por Chirieac, Lucian R.
Publicado no Transl Lung Cancer Res (2016)

Erratum to current state of immunotherapy for non-small cell lung cancer

Por Malhotra, Jyoti, Jabbour, Salma K., Aisner, Joseph
Publicado no Transl Lung Cancer Res (2017)

Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution

Por Salati, Massimiliano, Baldessari, Cinzia, Cerbelli, Bruna, Botticelli, Andrea
Publicado no Transl Lung Cancer Res (2018)

Lung cancer and chronic obstructive pulmonary disease: understanding the complexity of carcinogenesis

Por Mouronte-Roibás, Cecilia, Ruano-Raviña, Alberto, Fernández-Villar, Alberto
Publicado no Transl Lung Cancer Res (2018)

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Por Metro, Giulio, Di Maio, Massimo
Publicado no Transl Lung Cancer Res (2018)

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Por Addeo, Alfredo, Banna, Giuseppe Luigi
Publicado no Transl Lung Cancer Res (2018)

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Por Addeo, Alfredo, Banna, Giuseppe Luigi
Publicado no Transl Lung Cancer Res (2018)

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Por Metro, Giulio, Di Maio, Massimo
Publicado no Transl Lung Cancer Res (2018)

Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?

Por Perez-Gracia, Jose Luis, Sanmamed, Miguel F., Melero, Ignacio
Publicado no Transl Lung Cancer Res (2018)

Aromatase inhibitors combined with aspirin to prevent lung cancer in preclinical models

Por Young, Patricia A., Pietras, Richard J.
Publicado no Transl Lung Cancer Res (2018)

Biomarkers in the selection of maintenance therapy in non-small cell lung cancer

Por Tanner, Nichole T., Sherman, Carol A., Silvestri, Gerard A.
Publicado no Transl Lung Cancer Res (2012)